- Page 1: Clinical Practice Guideline on type
- Page 4 and 5: A bibliographic record of this work
- Page 8 and 9: 6.2. Impaired Glucose Tolerance (IG
- Page 10 and 11: Appendix 5. Coronary risk tables: R
- Page 13 and 14: Authors and collaborations Working
- Page 15 and 16: Questions to be answered Definition
- Page 17: 25. Is a diabetic nephropathy scree
- Page 20 and 21: C B D The use of omega 3 fatty acid
- Page 22 and 23: Insulin therapy A When an insulin t
- Page 24 and 25: B B When the response to the treatm
- Page 26 and 27: D C D A B D CPG Within the medical
- Page 29: 2. Scope and objectives The main ai
- Page 32 and 33: • Assessment of the quality of th
- Page 34 and 35: The studies carried out in Spain st
- Page 37 and 38: 5. Definition, natural history, cri
- Page 39 and 40: 5.2.5. Low weight at birth The rela
- Page 41 and 42: Green tea In a study (33) with 17,0
- Page 43 and 44: 5.3. DM 2 diagnosis 5.3.1. Diagnost
- Page 45 and 46: HbA 1 c could be used to diagnose d
- Page 47 and 48: and certain ethnic groups (Asian, C
- Page 49 and 50: 6. Diabetes prevention in patients
- Page 51 and 52: An SR (72) only includes patients w
- Page 53 and 54: 7. Diet and exercise The questions
- Page 55 and 56: An RCT analysed the effectiveness o
- Page 57 and 58:
The evidence on efficacy of the dif
- Page 59 and 60:
Recommendations D A B B B C B D The
- Page 61 and 62:
8. Glycemic control The questions t
- Page 63 and 64:
4 The guidelines examined agree to
- Page 65 and 66:
Its effectiveness has been recently
- Page 67 and 68:
2+ Glycemic control, achieved with
- Page 69 and 70:
On the other hand, the combined the
- Page 71 and 72:
tion of insulin and oral diabetic d
- Page 73 and 74:
glycaemia, slow or intermediate act
- Page 75:
1+ There are no significant differe
- Page 78 and 79:
9.1.1. Comparison of cardiovascular
- Page 80 and 81:
More studies with more patients are
- Page 82 and 83:
it is worth mentioning, that 19.2%
- Page 84 and 85:
9.5. Treatment for high blood press
- Page 86 and 87:
Regarding renal results, the slow p
- Page 89 and 90:
10. Screening and treatment of micr
- Page 91 and 92:
Recommendations B B The 45º non-my
- Page 93 and 94:
Regarding the ARB-II, in a clinical
- Page 95 and 96:
The effectiveness of antidepressive
- Page 97 and 98:
Recommendations A B B Tricyclic ant
- Page 99:
1+ Group psychotherapy can be more
- Page 102 and 103:
11.2. Methods to assess the foot at
- Page 104 and 105:
No subsequent RCTs have been found
- Page 106 and 107:
These inconsistencies suggest that
- Page 108 and 109:
The new dressings (hydrocolloid dre
- Page 110 and 111:
Oral antibiotics Five studies were
- Page 113 and 114:
12. Diabetologic education The ques
- Page 115 and 116:
metabolic control (with significant
- Page 117 and 118:
Recommendations A D B A B A D Peopl
- Page 119 and 120:
13. Organization of the medical con
- Page 121 and 122:
Initial visits Diagnosis Control vi
- Page 123:
Cardiology • Coronary heart disea
- Page 126 and 127:
Table 2. Levels of evidence and gra
- Page 128 and 129:
Dieta 1500 kcal 126 CLINICAL PRACTI
- Page 130 and 131:
128 CLINICAL PRACTICE GUIDELINES IN
- Page 132 and 133:
Dieta 1750 kcal 130 CLINICAL PRACTI
- Page 134 and 135:
132 CLINICAL PRACTICE GUIDELINES IN
- Page 136 and 137:
Dieta 2000 kcal 134 CLINICAL PRACTI
- Page 138 and 139:
136 CLINICAL PRACTICE GUIDELINES IN
- Page 140 and 141:
Appendix 3. Hypoglycaemic drugs Vad
- Page 142 and 143:
Analogues Action profile Disposable
- Page 144 and 145:
Appendix 4. Hypoglycaemia treatment
- Page 146 and 147:
Appendix 5. Coronary risk tables: R
- Page 148 and 149:
Appendix 7. Drugs for neuropathic p
- Page 150 and 151:
Appendix 9. Education of the diabet
- Page 152 and 153:
150 CLINICAL PRACTICE GUIDELINES IN
- Page 154 and 155:
152 CLINICAL PRACTICE GUIDELINES IN
- Page 156 and 157:
Appendix 10. Assessment proposal. I
- Page 158 and 159:
Appendix 11. Glossary and abbreviat
- Page 160 and 161:
Abbreviations AA.CC Autonomous Comm
- Page 162 and 163:
Appendix 12. Declaration of interes
- Page 164 and 165:
16. Ryan EA, Imes S, Liu D, McManus
- Page 166 and 167:
49. Brunner EJ, Shipley MJ, Witte D
- Page 168 and 169:
80. IDF Clinical Guidelines Task Fo
- Page 170 and 171:
112. Inzucchi SE. Oral antihypergly
- Page 172 and 173:
142. Schwartz S, Sievers R, Strange
- Page 174 and 175:
171. Marrugat J, D’Agostino R, Su
- Page 176 and 177:
199. Vijan S. Hypertension in diabe
- Page 178 and 179:
227. Jennings DL, Kalus JS, Coleman
- Page 180 and 181:
263. Bouza C, Munoz A, Amate JM. Ef
- Page 182:
P.V.P.: 6 € www.msc.es